ROMA (Risk of Ovarian Malignancy Algorithm)
ورودیهای بالینی بیمار
حداقل ۱ — حداکثر ۱۰۰۰۰ • واحد: pmol/L
حداقل ۱ — حداکثر ۱۰۰۰۰۰ • واحد: U/mL
پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.
- Low risk (pre)0–11.4
- High risk11.4–100
The ROMA (Risk of Ovarian Malignancy Algorithm) calculates calculating gestational age, evaluating maternal-fetal wellbeing, and assessing perinatal complications. Key inputs include menopausal. Scores guide determining delivery timing, administering antenatal corticosteroids or tocolytics, and obstetric monitoring. This standardized assessment improves clinical decision safety and bedside patient management.
Clinical Guidelines & Evidence
Combines HE4, CA125 and menopausal status into a malignancy risk percentage for adnexal masses.
Clinical Indication
The ROMA (Risk of Ovarian Malignancy Algorithm) is indicated for bedside clinical practice to support Combines HE4, CA125 and menopausal status into a malignancy risk percentage for adnexal masses.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.
Target Population
Target population comprises Pregnant individuals across antepartum, intrapartum, and postpartum stages, or patients with acute gynecologic conditions. Clinical application is indicated across Labor and delivery suites, obstetric triage, antenatal clinics, and gynecologic surgical units.
Limitations & Contraindications
Normal gestational physiological adaptations alter baseline plasma volume, serum creatinine, and resting heart rate.
Clinical Pearls & Action Plan
Simultaneous surveillance of maternal hemodynamic stability and continuous electronic fetal heart rate monitoring is paramount.
PI pre: -12.0+2.38 ln(HE4)+0.0626 ln(CA125); PI post: -8.09+1.04 ln(HE4)+0.732 ln(CA125); ROMA = e^PI/(1+e^PI) x 100
Input Parameters
| Name | Type | Required | Description |
|---|---|---|---|
| menopausal | string | Yes | Menopausal status |
| he4 | float | Yes | HE4(pmol/L) |
| ca125 | float | Yes | CA125(U/mL) |
Score Interpretation & Guidance
| Range | Stage | Description |
|---|---|---|
| 0–11.4 | Low risk (pre) | Below high-risk cutoff |
| 11.4–100 | High risk | At/above high-risk cutoff |
Evidence-Based References (EBM)
- Moore RG, McMeekin DS, Brown AK, et al. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol. 2009;112(1):40-46.